FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) reported its third straight quarter of iPhone sales and revenue declines after the market closed on Tuesday. The tech giant's fourth-quarter profit trumped Wall Street expectations, while revenues fell short. Although, Apple reported its third straight year-over-year decline in iPhone... Buick, Lexus and Toyota are among the top brands with highest reliability rating in the latest annual brand reliability survey. A New York woman has filed a $20 million lawsuit against Kentucky Fried Chicken, accusing the fast-food giant of 'false and deceptive trade practice' and also of misleading customers as she did not get enough chicken in her $20 "Fill-Up."
comments powered by Disqus
Follow RTT